Melatonin and the Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
This trial seeks to compare the effects of melatonin supplementation versus placebo in subjects with the metabolic syndrome.

Detailed Description
-----------------
The primary purpose of this Phase II crossover design trial is to examine the safety and efficacy of 8mg of melatonin taken one hour before bedtime compared to a placebo treatment to improve at least one of the five components associated with the metabolic syndrome.

Official Title
-----------------
Melatonin Supplementation and the Metabolic Syndrome: A Phase II Crossover Design Clinical Trial

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Drug: Melatonin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 30-79 years. Diagnosed with metabolic syndrome according to AdenosineTriphosphate-III criteria. Availability for six months after enrolling in the study. Exclusion Criteria: Inability to understand informed consent and to cooperate with study procedures. Supplemental intake of melatonin. Current smoking. Current use of calcium channel blockers. Current, planned, or recent (12 months) participation in another clinical trial. Women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the next 6 months. Presence of any of the following diagnosed health conditions: Active malignancy other than nonmelanoma skin cancer (current therapy for this malignancy,diagnosis within five years of enrollment, recurrence within five years of enrollment, or metastasis) Uncontrolled hypothyroidism or hyperthyroidism Recent (< 1 year ago) history of heart attack, bypass surgery, angioplasty, or stroke Heart failure (New York Heart Association functional class 3 or 4) On renal dialysis Immunosuppressive therapy (systemic corticosteroids, azathioprine, methotrexate, cyclophosphamide, etc.) or an immunodeficiency syndrome Narcotic or alcohol dependence Obstructive sleep apnea (OSA) , defined either by previous diagnosis (with or without use of nasal CPAP), or by a score of 0.80 or higher on the MAP (Multivariate Apnea Prediction), a validated screening algorithm with high positive and negative predictive value for identifying OSA. Shift-workers.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Melatonin<br>Melatonin 8mg one hour before bedtime for 10 weeks | Drug: Melatonin<br>* 8 mg dose of Melatonin<br>|
| Placebo Comparator: Placebo<br>Placebo administered 1 hour before bedtime for 10 weeks | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic Syndrome Components |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood Pressure, Glucose levels, HDL levels, Triglyceride levels, Waist Circumference